Latest News
Servier acquires Edgewise Therapeutics' muscular dystrophy business
14 July 2026 - French pharmaceutical company Servier announced on Monday that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc (Nasdaq:EWTX) following regulatory clearance and customary closing conditio...
US FDA accepts BioMarin's sNDA for full approval of VOXZOGO (vosoritide) for children with achondroplasia
14 July 2026 - Rare disease biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) announced on Monday that the US Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for VOXZOGO (vosor...
Eisai reports new data showing etalanetug reduces Alzheimer's Disease tau tangle‑specific biomarker
13 July 2026 - Japanese pharmaceutical company Eisai Co., Ltd. (TYO: 4523) on Monday reported new findings showing that its investigational anti-MTBR antibody etalanetug (E2814) reduced levels of plasma eMTBR-tau243, a biomarker linked to tau tangle ...
Takeda and Indonesia launch partnership to expand plasma-derived medicine production
13 July 2026 - Japanese pharmaceutical company Takeda (TSE:4502) (NYSE:TAK) announced on Monday that it has entered into a multi-year collaboration with the Indonesian government to strengthen the country's plasma ecosystem, following the Minist...
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
13 July 2026 - Swedish pharmaceutical company Newbury Pharmaceuticals AB (STO:NEWBRY) announced on Monday that it has received marketing authorisation in Sweden for Tofacitinib Newbury 5 mg and 10 mg film-coated tablets, marking the first approval in...